

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September, 2024

Commission File No. 001-39621

---

**OPTHEA LIMITED**  
(Translation of registrant's name into English)

---

Level 4  
650 Chapel Street  
South Yarra, Victoria, 3141  
Australia  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

---

---

## EXHIBIT INDEX

Exhibit	Description
99.1	<a href="#"><u>Press Release: Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**OPTHEA LIMITED**

(Registrant)

By: /s/ Frederic Guerard

Name: Frederic Guerard

Title: Chief Executive Officer

Date: 09/03/2024

---



## ASX, Nasdaq and Media Release

3rd September, 2024

### Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Melbourne, Australia, and Princeton, NJ, US, September 3, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024:

#### H.C. Wainwright 26th Annual Global Investment Conference

Presentation: Monday, September 9, 2024, 7:00 AM ET

Presenter: Frederic Guerard, PharmD, CEO

The webcast will be accessible via the link:

<https://journey.ct.events/view/19df556a-f376-4c6d-af5b-d8220d561640>

#### Cantor 2024 Global Healthcare Conference

Presentation: Thursday, September 17, 2024, 8:35 AM ET

Presenter: Frederic Guerard, PharmD, CEO

The webcast will be accessible via the link: <https://wsw.com/webcast/cantor22/register.aspx?conf=cantor22&page=opt&url=https://wsw.com/webcast/cantor22/opt/1938033>,

The webcasts of both presentations can also be accessed under "Events & Presentations" in the Investor Relations section of the Company's website, [www.opthea.com](http://www.opthea.com).

#### About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

---



To learn more, visit our website at [www.opthea.com](http://www.opthea.com) and follow us on X and LinkedIn.

**Authorized for release to ASX by Fred Guerard, PharmD, CEO, Opthea**

**Investor Inquiries**

PJ Kelleher  
LifeSci Advisors LLC  
Email: [pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)  
Phone: 617-430 7579

***Join our email database to receive program updates:***

Tel: +61 (0) 3 9826 0399  
Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

**Media Inquiries**

Silvana Guerci-Lena  
NorthStream Global Partners  
[silvana@nsgpllc.com](mailto:silvana@nsgpllc.com)

**Source: Opthea Limited**

---

